

Contents

Welcome Address	iii
EULAR 2017 Abstracts Reviewers	iv

Speakers Abstracts

Speaker Presentations

Wednesday, 14 June 2017

SP0001–SP0004	Joint EULAR - APLAR session: novel animal models - where no researcher has gone before...	2
SP0005–SP0008	Health professional welcome session	2
SP0009	WIN & HOT session	3
SP0010–SP0012	Moving towards new criteria in SLE, Sjögren's and APS	4
SP0013–SP0016	The differential diagnosis of diffuse skin sclerosis and of Raynaud's phenomenon and a practical approach to assessment	5
SP0017–SP0018	Controlling the balance between cancer and autoimmunity	5
SP0019–SP0021	Fibromyalgia: a disease of the peripheral or central nervous system	6
SP0022	Chondrocyte channels (role in mechanotransduction)or "channeling the chondrocyte"	6
SP0023–SP0024	Wearable technologies in 21 st century healthcare	7
SP0025–SP0027	Assessment and management of osteoporosis	7
SP0028–SP0030	Systematic literature review: the link from science to clinical practice	8
SP0031–SP0033	EULAR Campaign: Don't Delay, Connect Today	8
SP0034–SP0036	Standing Committee session on paediatric rheumatology	9
SP0037–SP0040	Ultrasound basic I & II	10
SP0041–SP0043	Rehabilitation and modern drug treatment - needs and challenges	10
SP0044–SP0046	Comorbidities: having one RMD is enough - we don't need anything else	11

Thursday, 15 June 2017

SP0047–SP0049	Cytokines and chemokines	11
SP0050–SP0052	Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design	12
SP0053	WIN & HOT session	13
SP0054–SP0056	Treat-to-target in axSpA: reality or utopy?	13
SP0057–SP0058	Calcium crystal deposition in rheumatic diseases	14
SP0059–SP0060	Fifty shades of remission in RA	15
SP0061–SP0063	Innate immunity	15
SP0064–SP0066	To be and to become: transition from paediatric to adult care	16
SP0067–SP0068	Heterogeneity in JIA	16
SP0069–SP0070	EULAR - EMA session	17
SP0071–SP0073	Barrier free employment for young people with RMDs	17
SP0074	Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal	18
SP0075–SP0077	Ultrasound advanced I & II	19
SP0078–SP0079	PsA: an integrated perspective	19
SP0080	Autoinflammatory diseases in children and adults	20
SP0081–SP0083	Immunogenicity of biologics; myth or reality?	20
SP0084–SP0085	Which target / outcome is more relevant in the management of SLE?	21
SP0086–SP0087	Joint EULAR - EFIS session: Tilting the balance: from disease to tolerance induction	21
SP0088–SP0090	What to do about comorbidity?	22
SP0091	Data visualisation: tables and graphs for publication and presentation I & II	23
SP0092–SP0094	Difficult to reach patient groups	23
SP0095–SP0097	EULAR Projects in musculoskeletal imaging	24

SP0098–SP0100	Capillaroscopy I & II	24
SP0101–SP0103	Ultrasound, clinical, diagnostic and therapeutic skills I & II	25
SP0104–SP0105	Macrophage M2 polarization: implications in fibrotizing diseases	26
Friday, 16 June 2017		
SP0106	Mucosal B cells: gatekeepers of immune function	26
SP0107	WIN & HOT session	27
SP0108	Comorbidities in rheumatoid arthritis	27
SP0109–SP0110	Life-threatening presentation of rheumatic diseases	27
SP0111	AxSpA: From bug to gut and to disease phenotype	28
SP0112–SP0114	Pregnancy meets rheumatic patients	28
SP0115–SP0116	Neuronal and hormonal alterations in arthritis	29
SP0117–SP0120	Fighting osteoporosis fragilities	29
SP0121–SP0122	Biological agents in juvenile idiopathic arthritis: open issues	30
SP0123–SP0124	Health equity and economy - a vital relationship	31
SP0125–SP0127	Biomarkers in cardiovascular rheumatology - state-of-the-art 2017	31
SP0128–SP0129	MRI I & II	32
SP0130	WIN & HOT session	32
SP0131–SP0133	What is behind vasculitis?	33
SP0134	Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs	33
SP0135–SP0137	Regulatory molecules in connective tissue	33
SP0138–SP0140	Patient engagement in research: best practices, benefits, and challenges	34
SP0141–SP0142	RA treatment in patients wanting to become pregnant - interactive session	35
SP0143–SP0144	Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of Biosimilars in RMDs	35
SP0145–SP0148	From pre-RA to established RA	35
SP0149	Laboratory course - from the clinic to the lab and back II	36
SP0150–SP0151	Switching T on and off: how T cells drive and regulate chronic inflammation	36
Saturday, 17 June 2017		
SP0152–SP0153	Reverse translation - learning from clinical trials in SLE, Sjögren's and APS	37
SP0154–SP0156	Genomic imprinting and post-translational modifications	37
SP0157–SP0158	Optimizing treatment for osteoarthritis: take the phenotype in account "one size does not fit all" ..	38
SP0159–SP0162	Targeting adipose tissue inflammation	38
SP0163–SP0165	Trials and tribulations of medication adherence	39
SP0166	Outcome in juvenile idiopathic arthritis	40
SP0167	Getting financial support to research in RMDs through horizon 2020: opportunities, good practices, and successful experiences	41
SP0168–SP0171	EULAR Projects - challenging projects in education and training	41
SP0172–SP0174	Workshop: strengthening your organisation - how to manage volunteers	42
SP0175	WIN & HOT session	42
SP0176–SP0177	Systemic sclerosis	42
SP0178	How diet influences musculoskeletal diseases	43
SP0179–SP0180	Can targeting disease activity in hand osteoarthritis improve our treatment in the 21 st century	43
SP0181–SP0184	Why we do develop autoimmunity	44
SP0185–SP0188	Closing the gap between objective measures and self-report in fibromyalgia	45
SP0189	Interactive cases from the HOT and WIN sessions	45
SP0190	Suffering in silence. Optimizing the management of psychological well-being for people with RMDs	46
SP0191–SP0194	Showcasing the EULAR Online Course for Health Professionals	46
SP0195	HPR Highlight session	47

Scientific Abstracts

Oral Presentations

Wednesday, 14 June 2017

OP0001–OP0002 OP0003–OP0004 OP0005–OP0006 OP0007–OP0008 OP0009–HPR OP0010 OP0011 OP0012–PARE OP0013–OP0014 OP0015–OP0022 OP0023–OP0030 OP0031–OP0038 OP0039–OP0046 OP0047–OP0054 OP0055–HPR OP0056–OP0063 OP0064–OP0071 OP0072–PARE OP0073–OP0080 OP0081–OP0088 OP0089–OP0096	Moving towards new criteria in SLE, Sjögren's and APS 50 Controlling the balance between cancer and autoimmunity 51 Fibromyalgia: a disease of the peripheral or central nervous system 52 Chondrocyte channels (role in mechanotransduction) or "channeling the chondrocyte" 53 Wearable technologies in 21 st century healthcare 53 Assessment and management of osteoporosis 54 Systematic literature review: the link from science to clinical practice 54 EULAR Campaign: Don't Delay, Connect Today 55 Standing Committee session on paediatric rheumatology 55 Still breaking news on TNF inhibitors in rheumatoid arthritis 56 Progress in management of SpA 60 Early diagnosis of systemic sclerosis and myositis: biomarkers and diagnostic tool 64 SLE, Sjögren's and APS - clinical aspects 67 Osteoporosis treatment gap, new options and new strategies 70 Rehabilitation and modern drug treatment - needs and challenges 73 Basic and clinical science in paediatric rheumatology 74 Impact of rheumatic diseases 78 Comorbidities: having one RMD is enough - we don't need anything else 81 Risk factors for developing diseases or comorbidities 82 Scleroderma, myositis and related syndromes, etiology, pathogenesis 85 Novel insights in inflammatory mediators 89
---	--

Thursday, 15 June 2017

OP0097 OP0098–OP0105 OP0106–OP0113 OP0114–OP0121 OP0122–OP0129 OP0130–OP0137 OP0138–HPR–OP0145–HPR OP0146–OP0153 OP0154–OP0161 OP0162–PARE–OP0163–PARE OP0164–OP0171 OP0172–OP0179 OP0180–OP0187 OP0188–OP0189 OP0190–OP0191 OP0192 OP0193–OP0194 OP0195 OP0196–OP0197 OP0198–PARE–OP0199–PARE OP0200 OP0201–OP0202 OP0203–OP0204 OP0205–OP0206 OP0207–OP0208 OP0209–HPR OP0210–PARE–OP0211–PARE OP0212–OP0213	Cytokines and chemokines 92 Progress in biological treatment of RA 92 PsA: a fascinating disease 96 More or less imaging in axial SpA? 100 Clinical and therapeutical news in systemic sclerosis 103 Vasculitis clinical and pathogenic highlights 107 HPR mind over matter - patients perspectives 110 RA: really a systemic disease? 113 Advances in RA and SpA pathophysiology 116 Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design 119 Osteoarthritis: new horizons for treatment 119 Cellular drivers of inflammation in rheumatic disease 123 Joint health & joint damage: a tale of three tissues 126 Treat-to-target in axSpA: reality or utopy? 129 Calcium crystal deposition in rheumatic diseases 130 Fifty shades of remission in RA 131 Innate immunity 131 To be and to become: transition from paediatric to adult care 132 Heterogeneity in JIA 132 Barrier free employment for young people with RMDs 133 Epidemiology of rheumatic and musculoskeletal diseases - a critical appraisal 134 PsA: an integrated perspective 135 Immunogenicity of biologics; myth or reality? 136 Which target/outcome is more relevant in the management of SLE? 137 Joint EULAR - EFIS session: tilting the balance: from disease to tolerance induction 138 What to do about comorbidity? 139 Difficult to reach patient groups 139 Macrophage M2 polarization: implications in fibrotizing diseases 140
---	--

Friday, 16 June 2017

OP0214–OP0215	Mucosal B cells: gatekeepers of immune function	141
OP0216–OP0223	PsA: the options grow!	141
OP0224–LB0003	From classics to new: synthetic DMARDs in RA	146
OP0231–LB0002	New treatments in SLE, Sjögren's and APS	150
OP0238–OP0245	Axial spondyloarthritis from risk factors to clinical outcomes	153
OP0246–OP0253	RA - causes and courses	157
OP0254–HPR–OP0261–HPR	HPR move to improve	161
OP0262–OP0269	Gout: advances in diagnosis and management	164
OP0270–LB0001	Low back pain and fibromyalgia	168
OP0276–PARE–OP0282–PARE	PARE abstract session	171
OP0283–OP0290	Imaging and treatment response in rheumatology	173
OP0291–OP0298	From genetics through epigenetics to proteomics: understanding disease mechanisms	177
OP0299–OP0306	Innovative insights into mechanism of SLE, Sjögren's and APS	180
OP0307–OP0308	Comorbidities in rheumatoid arthritis	182
OP0309	AxSpA: from bug to gut and to disease phenotype	183
OP0310–OP0311	Pregnancy meets rheumatic patients	184
OP0312–OP0313	Neuronal and hormonal alterations in arthritis	184
OP0314–HPR	Fighting osteoporosis fragilities	185
OP0315–OP0316	Biological agents in juvenile idiopathic arthritis: open issues	186
OP0317–PARE–OP0318–PARE	Health equity and economy - a vital relationship	186
OP0319	Biomarkers in cardiovascular rheumatology - state-of-the-art 2017	187
OP0320–OP0321	What is behind vasculitis?	187
OP0322	Cytokine taxonomy: reflection in the therapy of arthritides and other IMIDs	188
OP0323–OP0324	Personalised care for back pain	188
OP0325–OP0326	Regulatory molecules in connective tissue	189
OP0327–PARE	Patient engagement in research: best practices, benefits and challenges	190
OP0328–PARE	Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs	190
OP0329–OP0330	Switching T on and off: how T cells drive and regulate chronic inflammation	191

Saturday, 17 June 2017

OP0331	Reverse translation - learning from clinical trials in SLE, Sjögren's and APS	192
OP0332–OP0333	Genomic imprinting and post-translational modifications	192
OP0334–OP0335	Optimizing treatment for osteoarthritis: take the phenotype in account "one size does not fit all"	193
OP0336	Targeting adipose tissue inflammation	194
OP0337–HPR	Trials and tribulations of medication adherence	194
OP0338	Outcome in juvenile idiopathic arthritis	195
OP0339	Systemic sclerosis	195
OP0340	How diet influences musculoskeletal diseases	196
OP0341–OP0342	Can targeting disease activity in hand osteoarthritis improve our treatment in the 21 st century	196
OP0343	Why we do develop autoimmunity	197
OP0344–HPR	Closing the gap between objective measures and self-report in fibromyalgia	198
OP0345–PARE–OP0346–PARE	Suffering in silence. Optimizing the management of psychological well-being for people with RMDs	198
OP0347–HPR	Showcasing the EULAR Online Course for Health Professionals	199

Late Breaking Abstracts**Friday, 16 June 2017**

LB0001	Low back pain and fibromyalgia	170
LB0002	New treatments in SLE, Sjögren's and APS	153
LB0003	From classics to new: synthetic DMARDs in RA	149

Poster Presentations

Thursday, 15 June 2017

Guided Poster Tours

T1:	THU0001–THU0010	Genetic basis, epigenetics and genomics in disease	200
T2:	THU0025–THU0034	Inflammatory mediators in rheumatic disease	208
T3:	THU0068–THU0077	RA disease course and prognosis	224
T4:	THU0168–THU0176	MTX, GCs and JAK inhibitors in RA	265
T5:	THU0216–THU0225	Pathomechanism in SLE, SS, APS	286
T6:	THU0246–THU0257	Novelty in the clinical approach to SLE, Sjögren's and APS I	297
T7:	THU0294–THU0303	Vasculitis clinical aspects I	314
T8:	THU0345–THU0354	Progress in management of spondyloarthritis	334
T9:	THU0401–THU0410	A stroll among the crystals	359
T10:	THU0486–THU0495	Paediatric rheumatology	390
T11:	THU0538–THU0547	Clinical features and treatment of orphan diseases	410
T12:	THU0596–THU0605	Rheumatology training and disease burden	431
T13:	THU0648–THU0657	Economical impact of biosimilars and discussing risks with patients	450
T14:	THU0695–THU0704	Outcomes across all rheumatology	470

Posters

THU0001–THU0024	Genomics, genetic basis of disease and HLA / T cell recognition	200
THU0025–THU0067	Cytokines and inflammatory mediators	208
THU0068–THU0115	Rheumatoid arthritis - prognosis, predictors and outcome	224
THU0116–THU0167	Rheumatoid arthritis - comorbidity and clinical aspects	245
THU0168–THU0215	Rheumatoid arthritis - non biologic treatment	265
THU0216–THU0245	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	286
THU0246–THU0293	SLE, Sjögren's and APS - clinical aspects (other than treatment)	297
THU0294–THU0344	Vasculitis	314
THU0345–THU0400	Spondyloarthritis - treatment	334
THU0401–THU0467	Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis ..	359
THU0468–THU0483	Fibromyalgia	384
THU0484–THU0485	Basic science in paediatric rheumatology	389
THU0486–THU0537	Paediatric rheumatology	390
THU0538–THU0579	Other orphan diseases	410
THU0580–THU0598	Education	425
THU0599–THU0657	Public health, health services research and health economics	432
THU0658–THU0704	Validation of outcome measures and biomarkers	455
THU0705–THU0719	Rehabilitation	474

Friday, 16 June 2017

Guided Poster Tours

F1:	FRI0022–FRI0031	RA stromal cells - reloaded	487
F2:	FRI0129–FRI0138	RA all over the body	529
F3:	FRI0179–FRI0190	TNF inhibitors in RA = always and again	548
F4:	FRI0212–FRI0222, FRI0178	Trends in non-TNF alpha biologicals for RA I	562, 548
F5:	FRI0255–FRI0265	Novelty in the clinical approach to SLE, Sjögren's and APS II	582
F6:	FRI0303–FRI0312	Vasculitis clinical aspects II	601
F7:	FRI0353–FRI0362	Scleroderma and myositis: etiology	620
F8:	FRI0363–FRI0372	Indexes and predictors in systemic sclerosis and myositis	624
F9:	FRI0420–FRI0423, FRI0080–FRI0084	New drivers in RA and SpA pathophysiology	645, 507
F10:	FRI0472–FRI0481	Outcome in AxSpA: does it matter?	665
F11:	FRI0524–FRI0533	Osteoporosis risk assessment and treatment: new tools and new strategies	689
F12:	FRI0582–FRI0591	What's new in orphan diseases	709
F13:	FRI0623–FRI0632	Imaging advances in arthritis - what is new?	724
F14:	FRI0683–FRI0692	Risk factors for RMDs or comorbid conditions	748

Posters

FRI0001–FRI0021	Cartilage, synovium and osteoimmunology	480
FRI0022–FRI0084	Rheumatoid arthritis - etiology, pathogenesis and animal models	487
FRI0085–FRI0128	Rheumatoid arthritis - prognosis, predictors and outcome	509
FRI0129–FRI0177	Rheumatoid arthritis - comorbidity and clinical aspects	529
FRI0178–FRI0211	Rheumatoid arthritis - anti-TNF therapy	548
FRI0212–FRI0254	Rheumatoid arthritis - other biologic treatment	562
FRI0255–FRI0302	SLE, Sjögren's and APS - clinical aspects (other than treatment)	582
FRI0303–FRI0352	Vasculitis	601
FRI0353–FRI0362	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	620
FRI0363–FRI0419	Scleroderma, myositis and related syndromes	624
FRI0420–FRI0429, FRI0431	Spondyloarthritis - etiology, pathogenesis and animal models	645, 649
FRI0430–FRI0481	Spondyloarthritis - clinical aspects (other than treatment)	649
FRI0482–FRI0523	Psoriatic arthritis	670
FRI0524–FRI0581	Osteoporosis	689
FRI0582–FRI0622	Other orphan diseases	709
FRI0623–FRI0682	Diagnostics and imaging procedures	724
FRI0683–FRI0731	Epidemiology, risk factors for disease or disease progression	748

Saturday, 17 June 2017**Guided Poster Tours**

S1: SAT0010–SAT0019	Innate mediators and autoantibodies in rheumatic disease	772
S2: SAT0027–SAT0036	How B and T cells contribute to rheumatic disease	777
S3: SAT0037–SAT0046	RA - risk factors and consequences	781
S4: SAT0088–SAT0097	From the heart of rheumatology	802
S5: SAT0176–SAT0187	Trends in non-TNF alpha biologicals for RA II	836
S6: SAT0219–SAT0230	New treatment options in SLE, Sjögren's and APS	856
S7: SAT0312–SAT0321	SSc, myositis and rare diseases: etiology and animal models	890
S8: SAT0372–SAT0381	Last news on systemic sclerosis and myositis	911
S9: SAT0433–SAT0441	A walk through PsA progress	935
S10: SAT0483–SAT0494	Steps forward in osteoarthritis research	958
S11: SAT0556–SAT0565	Infection related rheumatic disease: clinical and epidemiologic aspects	987
S12: SAT0609–SAT0618	Imaging advances in vasculitis, crystal and connective tissue disease	1004
S13: SAT0669–SAT0678	Comorbidities and outcomes in RMDs	1027

Posters

SAT0001–SAT0016	Innate immunity in rheumatic diseases	769
SAT0017–SAT0036	Adaptive immunity (T cells and B cells) in rheumatic diseases	774
SAT0037–SAT0087	Rheumatoid arthritis - prognosis, predictors and outcome	781
SAT0088–SAT0139	Rheumatoid arthritis - comorbidity and clinical aspects	802
SAT0140–SAT0175	Rheumatoid arthritis - anti-TNF therapy	821
SAT0176–SAT0218	Rheumatoid arthritis - other biologic treatment	836
SAT0219–SAT0261	SLE, Sjögren's and APS - treatment	856
SAT0262–SAT0311	SLE, Sjögren's and APS - clinical aspects (other than treatment)	873
SAT0312–SAT0324	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	890
SAT0325–SAT0381	Scleroderma, myositis and related syndromes	895
SAT0382–SAT0432	Spondyloarthritis - clinical aspects (other than treatment)	916
SAT0433–SAT0482	Psoriatic arthritis	935
SAT0483–SAT0555	Osteoarthritis	958
SAT0556–SAT0582	Infection-related rheumatic diseases	987
SAT0583–SAT0608	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	996
SAT0609–SAT0668	Diagnostics and imaging procedures	1004
SAT0669–SAT0716	Epidemiology, risk factors for disease or disease progression	1027

Abstracts Accepted for Publication

AB0001–AB0009	Genomics, genetic basis of disease and HLA/T cell recognition	1047
AB0010–AB0020	Adaptive immunity (T cells and B cells) in rheumatic diseases	1050

AB0021–AB0025	Innate immunity in rheumatic diseases	1054
AB0026–AB0058	Cytokines and inflammatory mediators	1055
AB0059–AB0075	Cartilage, synovium and osteoimmunology	1067
AB0076–AB0111	Rheumatoid arthritis - etiology, pathogenesis and animal models	1073
AB0112–AB0120	Spondyloarthritis - etiology, pathogenesis and animal models	1085
AB0121–AB0163	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	1089
AB0164–AB0186	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	1104
AB0187–AB0188	Basic science in paediatric rheumatology	1112
AB0189–AB0289	Rheumatoid arthritis - prognosis, predictors and outcome	1113
AB0290–AB0373	Rheumatoid arthritis - comorbidity and clinical aspects	1149
AB0374–AB0394	Rheumatoid arthritis - anti-TNF therapy	1179
AB0395–AB0416	Rheumatoid arthritis - other biologic treatment	1186
AB0417–AB0441	Rheumatoid arthritis - non biologic treatment	1196
AB0442–AB0470	SLE, Sjögren's and APS - treatment	1204
AB0471–AB0548	SLE, Sjögren's and APS - clinical aspects (other than treatment)	1215
AB0549–AB0597	Vasculitis	1243
AB0598–AB0682	Scleroderma, myositis and related syndromes	1260
AB0683–AB0708	Spondyloarthritis - treatment	1292
AB0709–AB0736	Spondyloarthritis - clinical aspects (other than treatment)	1302
AB0737–AB0794	Psoriatic arthritis	1312
AB0795–AB0819	Osteoarthritis	1336
AB0820–AB0860	Osteoporosis	1345
AB0861–AB0901	Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis ..	1357
AB0902–AB0922	Infection-related rheumatic diseases	1371
AB0923–AB0932	Fibromyalgia	1378
AB0933–AB0943	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	1382
AB0944–AB0975	Paediatric rheumatology	1385
AB0976–AB0996	Other orphan diseases	1396
AB0997–AB1074	Diagnostics and imaging procedures	1403
AB1075–AB1115	Public health, health services research and health economics	1431
AB1116–AB1160	Epidemiology, risk factors for disease or disease progression	1446
AB1161–AB1176	Validation of outcome measures and biomarkers	1461
AB1177–AB1182	Rehabilitation	1467
AB1183–AB1194	Education	1469

Health Professionals in Rheumatology Abstracts

Oral Presentations

Wednesday, 14 June 2017

OP0009-HPR	Wearable technologies in 21 st century healthcare	53
OP0055-HPR	Rehabilitation and modern drug treatment - needs and challenges	73

Thursday, 15 June 2017

OP0138-HPR–OP0145-HPR	HPR mind over matter - patients perspectives	110
OP0209-HPR	What to do about comorbidity?	139

Friday, 16 June 2017

OP0254-HPR–OP0261-HPR	HPR move to improve	161
OP0314-HPR	Fighting osteoporosis fragilities	185

Saturday, 17 June 2017

OP0337-HPR	Trials and tribulations of medication adherence	194
OP0344-HPR	Closing the gap between objective measures and self-report in fibromyalgia	198
OP0347-HPR	Showcasing the EULAR Online Course for Health Professionals	199

Poster Presentations

Thursday, 15 June 2017

Guided Poster Tours

T15: THU0750-HPR–THU0759-HPR	HPR from top to toe; health professional practice	1486
------------------------------	---	------

Posters

THU0720-HPR–THU0751-HPR	HPR interventions (educational, physical, social and psychological)	1476
THU0752-HPR	HPR measuring health (development and measurement properties of PROs, tests, devices)	1487
THU0753-HPR–THU0755-HPR	HPR epidemiology and public health (including prevention)	1487
THU0756-HPR–THU0757-HPR	HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)	1488
THU0758-HPR	HPR professional education, training and competencies	1489
THU0759-HPR	HPR interventions (educational, physical, social and psychological)	1489
THU0760-HPR–THU0772-HPR	HPR service developments, innovation and economics in healthcare	1490

Friday, 16 June 2017

Posters

FRI0732-HPR–FRI0750-HPR	HPR measuring health (development and measurement properties of PROs, tests, devices)	1495
FRI0751-HPR–FRI0765-HPR	HPR epidemiology and public health (including prevention)	1502
FRI0766-HPR–FRI0772-HPR	HPR professional education, training and competencies	1507

Saturday, 17 June 2017

Guided Poster Tours

S14: SAT0717-HPR–SAT0725-HPR	Nursing and daily practice	1510
------------------------------	----------------------------------	------

Posters

SAT0717-HPR, SAT0719-HPR, SAT0723-HPR–SAT0724-HPR, SAT0726-HPR–SAT0770-HPR	HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)	1510, 1511, 1512, 1513
SAT0718-HPR	HPR measuring health (development and measurement properties of PROs, tests, devices)	1510
SAT0720-HPR	HPR service developments, innovation and economics in healthcare	1511
SAT0721-HPR–SAT0722-HPR	HPR epidemiology and public health (including prevention)	1511
SAT0725-HPR	HPR interventions (educational, physical, social and psychological)	1513

Abstracts Accepted for Publication

AB1195-HPR–AB1207-HPR	HPR measuring health (development and measurement properties of PROs, tests, devices)	1530
AB1208-HPR–AB1214-HPR	HPR epidemiology and public health (including prevention)	1534
AB1215-HPR–AB1230-HPR	HPR interventions (educational, physical, social and psychological)	1536
AB1231-HPR–AB1241-HPR	HPR patients' perspectives, functioning and health (descriptive: qualitative or quantitative)	1542
AB1242-HPR–AB1246-HPR	HPR service developments, innovation and economics in healthcare	1546
AB1247-HPR–AB1249-HPR	HPR professional education, training and competencies	1548

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

Wednesday, 14 June 2017

OP0012-PARE	EULAR Campaign: Don't Delay, Connect Today	55
OP0072-PARE	Comorbidities: having one RMD is enough - we don't need anything else	81

Thursday, 15 June 2017

OP0162-PARE–OP0163-PARE	Bringing rheumatology research to the next level: addressing the main challenges of patient partnerships in research and health care service design	119
-------------------------	---	-----

OP0198-PARE-OP0199-PARE	Barrier free employment for young people with RMDs	133
OP0210-PARE-OP0211-PARE	Difficult to reach patient groups	139
Friday, 16 June 2017		
OP0276-PARE-OP0282-PARE	PARE abstract session	171
OP0317-PARE-OP0318-PARE	Health equity and economy - a vital relationship	186
OP0327-PARE	Patient engagement in research: best practices, benefits and challenges	190
OP0328-PARE	Latest advances in the treatment and management of psoriatic arthritis and the latest news on the use of biosimilars in RMDs	190
Saturday, 17 June 2017		
OP0345-PARE-OP0346-PARE	Suffering in silence. Optimizing the management of psychological well-being for people with RMDs	198
Poster Presentations		
Thursday, 15 June 2017		
<i>Guided Poster Tours</i>		
T16: PARE0001–PARE0011	PARE - Poster tour I	1552
Friday, 16 June 2017		
<i>Guided Poster Tours</i>		
F17: PARE0012–PARE0022	PARE - Poster tour II	1556
Thursday, 15 June to Saturday, 17 June 2017		
<i>Posters</i>		
PARE0001	Building patient led organisations	1552
PARE0002	Arthritis research	1552
PARE0003	Work and rehabilitation	1552
PARE0004–PARE0007	Patient information and education	1553
PARE0008	Best practice campaigning	1554
PARE0009	Psychosocial support	1555
PARE0010	Arthritis research	1555
PARE0011	Best practice campaigning	1555
PARE0012–PARE0019	Patient information and education	1556
PARE0020–PARE0022	Building patient led organisations	1559
Abstracts Accepted for Publication		
AB1250-PARE-AB1251-PARE	Patient information and education	1560
AB1252-PARE-AB1253-PARE	Best practice campaigning	1560
Author Index		1563